BRIEF-GSK's Crohn's disease treatment fails in Phase III trial

Fri Aug 23, 2013 9:33am EDT

Related Topics

Aug 23 (Reuters) - GlaxoSmithKline Plc : * Announces phase III study of Vercirnon in patients with moderate-to-severe

Crohn's disease did not meet its primary endpoint * New recruitment and dosing in ongoing clinical programme has been suspended

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.